Oppenheimer Holdings Stock News

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32 nd Annual Healthcare Conference from March 15 th to 17 th .

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that company management will present a corporate overview at Oppenheimer''s…

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15 at 1:20 p.m. Eastern Time. To view the presentation, click Full story available on Benzinga.com

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA ), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer''s 32 nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET. The presentation can be accessed at https://bit.ly/3truAX8 or by visiting the investor relations section of the Company''s website at www.xoma.com . A replay of the presentation will be available and archived on the site for 90 days after … Full story available on Benzinga.com

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32 nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company''s Chief Executive Officer, will present at Oppenheimer''s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022. The presentation will be available beginning Tuesday, March 15, at 8:40 am ET (11:40 pm AEDT), and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/ . About Opthea Limited Opthea ((ASX:OPT, NASDAQ: OPT ) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea''s lead product candidate OPT-302 … Full story available on Benzinga.com

Immunocore to present at Oppenheimer’s 32 nd Annual Healthcare Conference

Immunocore to present at Oppenheimer''s 32 nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (NASDAQ: IMCR ), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the Oppenheimer 32 nd Annual Healthcare Conference. The presentation is scheduled for Wednesday, March 16, 2022 at 9:20 a.m. Eastern Time (ET). The presentation will be webcast live during the conference and will be available in the ‘Investors'' section of Immunocore''s website at www.immunocore.com . A replay of the presentation will be made available for a limited time. ## About Immunocore Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease.

Emerson <> edges higher as Oppenheimer upgrades shares to Outperform from Market Perform with a $110 price target, citing "excellent persistent capital preservation characteristics…

Oppenheimer has upgraded Nektar Therapeutics (NKTR) to outperform from perform given that the stock''s current risk/reward ratio is favorable.

Oppenheimer upgraded Booking Holdings (BKNG) to an Outperform rating after having it slotted with a Perform rating. Read more.

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical

Ghent, Belgium – 09 March 202 2 – Sequana Medical NV ( Euronext Brussels: SEQUA, the “Company” or “Sequana Medical” ) , an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following upcoming investor conferences in March 2022:

GHENT, Belgium, March 09, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following upcoming investor conferences in March 2022: BioCapital Europe , Amsterdam, 10 March 2022 Presentation by Ian Crosbie, CEO, on Thursday 10 March at 15:20 CET Oppenheimer''s 32 nd Annual Healthcare Conference , Virtual format, 15-17 March 2022 Presentation by Ian Crosbie, CEO, on Thursday 17 March at 10:00 am ET / 16:00 CET Sequana Medical will be meeting with international investors in 1-to-1 and small group meetings. Presentation slides will be available on Sequana Medical''s Investors website shortly after the events. For more information, please contact: Sequana Medical Lies Vanneste Director Investor Relations Tel: +32 498 05 35 79 Email: [email protected] LifeSci Advisors Guillaume van Renterghem Tel: +41 76 735 01 31 Email: [email protected] About Sequana Medical Sequana Medical is a commercial stage medical device company utilizing its proprietary alfa pump ® and DSR ® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

Oppenheimer has started the coverage on the clinical-stage biopharmaceutical company Fulcrum Therapeutics (FULC) with an Outperform recommendation citing the potential of FTX-6058,…